Abstract. Minimal pediatric data describe hospitalization causes and associated costs for children who receive maintenance hemodialysis, and no data exist to evaluate methods to decrease hospitalization. In 1999, two common causes of hemodialysis patient hospitalization at Texas Children's Hospital were fluid overload/hypertension (FO/HTN) and vascular ac-
Although recent pediatric data describe causes of mortality and a link between poor growth and hospitalization for children with ESRD (1) (2) (3) (4) (5) (6) , no published data evaluate potential therapeutic interventions addressing causes and costs for hospitalization for children who receive hemodialysis. Hospitalization interferes with a child's quality of life by interrupting family routines and preventing school attendance and normal socialization with peers (7) (8) (9) (10) (11) (12) . Practices that decrease pediatric hemodialysis patient hospitalization rates should improve aggregate health-related quality of life.
In 1999, we prospectively gathered hospitalization data for all children who were receiving maintenance hemodialysis at Texas Children's Hospital (Houston, TX) and found that two of the most common hospitalization causes were fluid overload/hypertension (FO/HTN; 41% of hospitalizations) and vascular access thrombosis (VAT; 41% of hospitalizations). Our center has previously reported improved fluid management and ultrafiltration (UF) practice guided by noninvasive monitoring of hematocrit (NIVM) during the hemodialysis treatment (13) and decreased VAT rates using an ultrasound dilution-guided proactive vascular access management protocol (14,15) for children who receive maintenance hemodialysis. The aim of the current study was to evaluate the effects of NIVM-guided ultrafiltration and ultrasound dilution-guided vascular access management practices on hospitalization rates and costs for children who receive maintenance hemodialysis.
Materials and Methods
All prevalent patients who received maintenance hemodialysis for at least 2 consecutive months in the Texas Children's Hospital Renal Dialysis Unit from January 1, 1999, through December 31, 2001, were identified. Hospitalization data were then obtained via a systematic review of dialysis unit monthly performance improvement meeting records, which detail the primary hospitalization causes for the previous month.
Hospitalization Categories
Each hospitalization was assigned on the basis of the primary diagnosis leading to hospitalization: (1) FO/HTN and (2) VAT and other. Categorization was based on the initial reason for hospital admission. Because the same pediatric nephrologists care for Texas Children's Hospital Dialysis Unit patients in the outpatient and inpatient settings and attend the monthly performance improvement meetings, hospitalization category assignment was reviewed and agreed on by the entire medical team each month. Hospitalizations were followed through January 2, 2002, when the final patient with FO/HTN was discharged from the hospital.
Indications for Hospitalization
In general, we hospitalized patients who were receiving hemodialysis for maintenance FO/HTN when pre-and posthemodialysis treatment BP were greater than the 99th percentile for age and height for more than 2 consecutive weeks. Patients with VAT were routinely hospitalized for 24 h minimum after thrombectomy to ensure vascular access patency. No changes in these practices were instituted over the course of study.
Definitions
"Hemodialysis patient days" refers to the number of days that maintenance hemodialysis was the designated ESRD treatment modality for a patient. Thus, a patient classified as a maintenance hemodialysis patient from March 1, 2001 , to April 1, 2001 , would contribute 31 hemodialysis days to the year 2001 total. "Patient census" refers to the number of individual patients who received maintenance hemodialysis as their maintenance ESRD treatment modality for 2 consecutive months during a given year.
Technological Interventions
In January 2000, we instituted a NIVM-guided UF practice to adjust UF rates and target dry weight achievement on the basis of the associations between NIVM monitor (Critline, Hemametrics, Kaysville, UT), blood volume changes, and intradialytic symptoms that we observed in our previous pediatric NIVM study (13) . In that study, (1) no patient demonstrated intradialytic symptoms with blood volume change Ͻ8% per hour in the first 90 min of treatment, and (2) 71% of symptoms that occurred in the last hour of treatment were associated with blood volume change of Ͼ4% per hour. Starting in January 2000, all patients received half of the prescribed UF volume in the first treatment hour up to a maximum blood volume change of 8 to 12% as depicted on the NIVM monitor. UF rates were then adjusted to attain the second half of the prescribed UF volume over the remaining treatment time (2 to 3 h). In the last treatment hour, patients received UF until they had hypotension or a blood volume change Ͼ4% per hour as noted by NIVM, at which point UF was discontinued for 5 min. When the NIVM monitor demonstrated refilling of the intravascular compartment, UF was resumed until the patient was symptomatic or a blood volume change of Ͼ4% per hour was noted again. When no intravascular refilling was seen after 5 min, the patient was determined to be at his or her target dry weight.
In January 2001, we instituted a policy of rapid referral for arteriovenous fistula or graft (permanent vascular access) angioplasty using monthly ultrasound dilution (Transonic HD01, Ithaca, NY) to assess vascular access flow. Children with a corrected vascular access flow of Ͻ650 ml/min per 1.73 m 2 were referred for balloon angioplasty within 48 h. We previously reported that this practice led to a 90% reduction in VAT rates and a 40% reduction in vascular access management costs (including increased costs for angioplasty) compared with our previous surveillance venography protocol (15) .
Data Analyzed
For each hospitalization, data obtained included the length of hospital stay (hospitalization days) and the hospitalization cost. To determine hospitalization rates, we divided the aggregate hospitalization days by the number of maintenance hemodialysis patient days for each year. We chose to define hospitalization rates in this manner, as opposed to the number of hospitalizations per year, because we wanted to assess the impact of each hospitalization on patient quality of life. Thus, the length of stay for each hospitalization and the resultant disruption of routine activity is a better measure for the current analysis.
Hospitalization cost data were available for all patients using the Eclipsys (formerly Transition Systems Incorporated) Decision Support system. The cost accounting function uses expenses from the general ledger, volume statistics from the Patient Accounting system, and relative value unit (RVU) data for every charge item. The general ledger expenses are grouped into cost types, and these expenses are spread on the basis of the volume and RVU. On the basis of these data, a cost is attached to each charge item associated with a patient's hospitalization. Cost data accounted for nondialysis nursing and allied health professional support care, supplies, and operating room expenses for thrombectomy/access revision and non-patient care-related overhead. Physician service costs were not included. Adjustments were made for item cost increases over each fiscal year during the study period. All cost data are reported based on an adjusted year 2001 basis.
Total hospitalization cost data for FO/HTN were adjusted for maintenance hemodialysis outpatient census by dividing the total cost by the aggregate Renal Dialysis Unit census (patient-years) for each calendar year from 1999 through 2001. Total cost data for VAT management were adjusted for patient census by dividing the total VAT cost by the aggregate patient census (patient-years) that received maintenance hemodialysis via a permanent vascular access for each calendar year from 2000 through 2001.
Statistical Analyses
The primary outcome variable, hospitalization rates (number of hospitalization days divided by outpatient maintenance hemodialysis days), was compared before and after intervention ( analysis. Potential associations between mean patient age, patient dry weight, and calendar year were assessed by one-way ANOVA. P Ͻ 0.05 was considered to be significant.
Results
Data reflecting the number of hemodialysis patient days, hemodialysis unit census, and patient demographics for each study year are shown in Table 1 . Both patient census and the total number of hemodialysis days are fairly constant from 1999 through 2001.
Fifty-one patients received maintenance hemodialysis in our center for at least 2 mo from 1999 through 2001. Mean patient weight (38.1 Ϯ 15.4 kg) was not different between any of the study years. Mean patient age increased over the study period (P Ͻ 0.001), which reflects, in part, some patients being maintained on hemodialysis for Ͼ1 yr during the study period.
Aggregate Hospitalization Data
The total number of hospitalization days for patients who were receiving maintenance hemodialysis demonstrates a steady increase over the study period (Table 2) , which resulted in a sixfold increase in hospitalization rates from 1999 (3. Table 2 for 21 d at a cost of $60,707 for VAT, despite the fact that there were more vascular access days in 2001 compared with 2000. Hospitalization for FO/HTN and VAT comprised significantly lower percentages of patient hospitalizations in the years after initiation of the NIVM and ultrasound dilution protocols (Table  2 ).
Hospitalization and Cost Data for FO/HTN and VAT

Discussion
The current pediatric study assesses the impact of technology driven ultrafiltration and vascular access surveillance practices on an important outcome measure, hospitalization rates. Application of two noninvasive technology-based clinical management protocols led to significant decreases in hospitalization rates for FO/HTN and VAT. The noninvasive monitoring of hematocrit-guided ultrafiltration protocol not only led to decreased hospitalization rates but also was associated with acceptable maintenance BP control, low antihypertensive medication requirement, and a decrease in additional outpatient hemodialysis treatments for FO/HTN in our pediatric hemodialysis population. Thus, the decrease in hospitalization rates secondary to FO/HTN observed from 1999 to 2000 and 2001 seems to be related to NIVM-guided target dry weight adjustments and did not come at the expense of chronic patient hypertension or result from multiple antihypertensive medication administration. Since the NIVM protocol clearly reduced the short-term morbidity of hospitalization, we suggest that the NIVM protocol could have a beneficial effect on the long-term cardiovascular disease, which has recently been shown to be the most common cause for mortality in children with ESRD (16) .
The ultrasound dilution-guided angioplasty referral protocol led to a significant decrease in patient hospitalization rates for VAT management. Our center recently reported permanent vascular access survival rates similar to those published for adults (17) . The significantly decreased VAT rates observed with our ultrasound dilution-guided angioplasty referral protocol could conceivably be associated with prolonged permanent vascular access functional survival and ultimately reduce the need for chronic catheter use for children who receive hemodialysis.
Hospitalization data from our center compares favorably to rates from adult hemodialysis patients reported from the United States Renal Data System (USRDS) (18) . All-cause hospitalization rates from the USRDS in 1998 to 2000 were 14.2 d per patient year, whereas hospitalization rates in our center were 3.7, 12.1, and 24.9 d per patient year for 1999, 2000, and 2001, respectively. The increase in hospitalization rates seen in our study resulted from a more aggressively defined hospitalization practice for patient malnutrition, which we instituted in 2000. With respect to cause-specific hospitalization data, the USRDS reports a rate of 12.7 d per patient-year for hypertension, whereas our observed rates for FO/HTN were 2.7, 0, and 0.2 d per patient-year over the time course studied. The USRDS provides no similar specific data for VAT (only vascular procedures are reported). McCarley et al. (19) noted a reduction in hospitalization rates for VAT from 1.8 to 0.4 d per patient-year at risk as a result of their ultrasound dilution protocol. We noted a reduction from VAT hospitalization rates from 3.6 to 1.5 d per patient-year after institution of our ultrasound dilution protocol. Pediatric VAT rates might be conceivably higher secondary to their relatively small vessels, although one might expect higher rates in adults secondary to diabetes-associated peripheral vascular disease.
It was not the purpose of the current study to report all-cause hospitalization rates for pediatric patients who receive maintenance hemodialysis, because such single-center data could be skewed by our local practice; all-cause data would be more applicable from registry data including the USRDS or the North American Renal Transplant Cooperative Study. Rather, we aimed to assess the impact of the application of two noninvasive technologies on two of the most common hospitalization causes observed previously in our program. Data from the current study demonstrate that pediatric hemodialysis patient morbidity and health care costs from hospitalization can be significantly reduced by application of the noninvasive methods in the manners described herein. These advances led to fewer missed school days, less separation from family and peers, and fewer invasive procedures. Additional research is required to determine whether these measures result in longterm improvements in patient health-related quality of life.
